Acorda Therapeutics (ACOR) Misses Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Acorda Provides Financial and Pipeline Update for Second Quarter 2017
July 27, 2017 6:00 AM EDTNDA submitted for INBRIJA (levodopa inhalation powder) Tozadenant Phase 3 data expected Q1 2018 AMPYRA® (dalfampridine) 2Q 2017 net revenue of $131.6 Million; 8% increase over 2Q 2016 AMPYRA 2017 net sales guidance of $535 - $545 million reiterated Projected year-end cash balance greater than $200 million
ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc.... More
